Events | 2012.04.21
GLORIATM-AF Registry Program investigating use of antithrombotic therapy in 56,000 patients with atrial fibrillation at risk of stroke announced
DUBAI, United Arab Emirates--(BUSINESS WIRE)--Boehringer Ingelheim announced today the launch of the GLORIATM-AF Registry Program, which is set to become the largest worldwide registry with the aim of understanding the long-term use of oral antithrombotic therapy in the prevention of non-valvular atrial fibrillation (AF)-related stroke in a real-world setting. With up to 56,000 patients planned for enrolment across 2,200 sites in 50 countries, GLORIATM-AF will study treatment regimes available f
For more information, please visit
http://www.businesswire.com/news/home/20[...]g-antithrombotic-therapy-56000
